stockportfolio.pro
Revolution Medicines, Inc. (RVMD)
Healthcare · Biotechnology · NasdaqGS
Revolution Medicines, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.16M | $50.04M | $42.98M | $29.39M | $35.38M | $11.58M | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $-41.79M | $-47.66M | $-108.16M | $-187.09M | $-248.71M | $-436.37M | $-600.09M | $-1.13B |
| Net margin | -207.2% | -95.2% | -251.6% | -636.6% | -703.0% | -3768.3% | — | — |
Source: Revolution Medicines, Inc. SEC filings (10-K).
Explore 8 years of Revolution Medicines, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RVMD in your portfolio →
Revolution Medicines, Inc. financial history by metric
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc. — frequently asked questions
What is Revolution Medicines, Inc.'s revenue?
Revolution Medicines, Inc. (RVMD) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Revolution Medicines, Inc. profitable?
No — RVMD reported a net loss of $-1.13B in fiscal 2025.
What is RVMD's P/E ratio?
Revolution Medicines, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Revolution Medicines, Inc. have?
As of fiscal year 2025, RVMD carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Revolution Medicines, Inc.'s market cap?
Revolution Medicines, Inc. (RVMD) has a market capitalization of about $31.27B, based on the latest data in our nightly-refreshed cache.
When does Revolution Medicines, Inc.'s fiscal year end?
RVMD's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Revolution Medicines, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.